FNDC11

Across TCGA pan-cancer cohorts, FNDC11 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FNDC11 data layer compared with 20 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher FNDC11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FNDC11 expression acts as an unfavorable survival marker.

BRCA, KICH, and PAAD are the cancer types where FNDC11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.207	0.924	<.001	36	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
PAAD	DFS	Median	All	0.112	0.504	.025	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
STAD	DFS	Median	III,IV	0.165	0.489	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FNDC11–BRCA (OS)

Open the BRCA breakdown →